Skip to main content

SeqWright Makes Second Investment in VisiGen; ABI Expected to Start Alliance Before End of Year

NEW YORK, Nov. 2 (GenomeWeb News) - SeqWright has made a much-anticipated and undisclosed follow-on investment in Visigen Biotechnologies, meeting a key condition that would have kept Applied Biosystems from making its own investment in the next-generation sequencing company, SeqWright and VisiGen said today.


As GenomeWeb News reported a year ago, SeqWright paid an undisclosed amount of cash for VisiGen stock to become a shareholder. The new investment helps clear the way for ABI to invest in and collaborate with VisiGen. The companies expect that VisiGen's collaboration with ABI will begin by the end of the calendar year.


VisiGen, based in Houston, is developing a real-time sequencing system to reduce the cost of DNA sequencing.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.